title: Cryopreserved Arterial Allografts and ABO and Rhesus Compatibility.
abstract: BACKGROUND
  Arterial cryopreserved allografts are conduit of choice for arterial bypass in case of infection. They are sometimes submitted to accelerated degeneration: stenosis, thrombosis, or aneurysmal evolution. We hypothesized that ABO group and Rhesus compatibility could play a role in arterial cryopreserved allograft complications.
  
  
  METHODS
  Patients who benefit from allograft bypass from 2006 to 2011 were retrospectively compared, regarding ABO or rhesus compatibility and irregular agglutinins.
  
  
  RESULTS
  Seventy-two patients were included. Regarding ABO mismatch, there was no difference in terms of death (51% vs. 43%, P = 0.820), thrombosis (25% vs. 32%, P = 0.78), rupture (9% vs. 0%, P = 0.247), stenosis (3% vs. 12%, P = 0.331), aneurysmal degeneration (16% vs. 12%, P = 1), and 5 years of secondary patency rate (34% vs. 39%, P = 0.141). There was also no difference regarding Rhesus mismatch.
  
  
  CONCLUSIONS
  Allograft degeneration does not seem to be related to ABO mismatch. This degeneration could be related to another way of immunogenicity, particularly Human Leukocyte Antigen mismatch, and needs further exploration.
authors.affiliation: Department of Vascular and Endovascular Surgery, University Hospital of Lyon, Lyon Cedex 03, France; Faculté de Médecine Laennec, Université Claude Bernard - Lyon 1, Villeurbanne, France. Electronic address: dellaschiava.nellie@neuf.fr.
authors.forename: Nellie
authors.initials: N
authors.lastname: Della Schiava
authors.affiliation: Department of Vascular and Endovascular Surgery, University Hospital of Lyon, Lyon Cedex 03, France; Faculté de Médecine Laennec, Université Claude Bernard - Lyon 1, Villeurbanne, France.
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Mathevet
authors.affiliation: Department of Vascular and Endovascular Surgery, University Hospital of Lyon, Lyon Cedex 03, France.
authors.forename: Tarek
authors.initials: T
authors.lastname: Boudjelit
authors.affiliation: Department of Vascular and Endovascular Surgery, University Hospital of Lyon, Lyon Cedex 03, France; Faculté de Médecine Laennec, Université Claude Bernard - Lyon 1, Villeurbanne, France.
authors.forename: Matthieu
authors.initials: M
authors.lastname: Arsicot
authors.affiliation: Department of Vascular and Endovascular Surgery, University Hospital of Lyon, Lyon Cedex 03, France; Faculté de Médecine Laennec, Université Claude Bernard - Lyon 1, Villeurbanne, France.
authors.forename: Patrick
authors.initials: P
authors.lastname: Feugier
authors.affiliation: Department of Vascular and Endovascular Surgery, University Hospital of Lyon, Lyon Cedex 03, France; Faculté de Médecine Laennec, Université Claude Bernard - Lyon 1, Villeurbanne, France.
authors.forename: Patrick
authors.initials: P
authors.lastname: Lermusiaux
authors.affiliation: Department of Vascular and Endovascular Surgery, University Hospital of Lyon, Lyon Cedex 03, France; Faculté de Médecine Laennec, Université Claude Bernard - Lyon 1, Villeurbanne, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Millon
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology*; D064591:Allografts; D000783:Aneurysm / Q000276:immunology / Q000503:physiopathology; D001158:Arteries / Q000276:immunology / Q000503:physiopathology / Q000637:transplantation*; D001705:Bioprosthesis; D001807:Blood Vessel Prosthesis; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D015925:Cryopreservation; D005260:Female; D006083:Graft Occlusion, Vascular / Q000276:immunology / Q000503:physiopathology; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival; D006648:Histocompatibility; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D012189:Retrospective Studies; D012204:Rh-Hr Blood-Group System / Q000276:immunology*; D012307:Risk Factors; D013927:Thrombosis / Q000276:immunology / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome; D014654:Vascular Patency
chemical_list: D000017:ABO Blood-Group System; D012204:Rh-Hr Blood-Group System